What more do you think is going on in genetic short sleepers? I can’t for the life of me figure it out. My sleep is excellent— both rem and deep and overall sleep duration and consolidation. But if anything I feel like I’ve inherited a long sleep mutation and I NEED a ton of sleep. And it’s becoming harder with age to keep full wakefulness and alertness throughout the day (though I suspect a big part of that is my environment being under stimulating to what I’ve been used to). But if I could take a drug that kept me super alert during the day without jitters and even lowered my need for sleep so I can wake up at 5:30 am and not suffer — neither psychologically nor physiologically — that would be amazing.
1 Like
I don’t know what more is going on but I suspect it is more than just more orexin production. Perhaps a more optimal metabolization, or slower aging of different neurons. Scientists really need to figure this one out and create an intervention to make everyone a “short sleeper”.
I believe that optimization of sleep is one of the best ways we can improve longevity.
I wrote about my theory here Sleep 2.0 – Understanding and Upregulating the Rejuvenating Aspects of Good Sleep
1 Like
A new podcast interview with the CEO of Alkermes, with lots of discussion on the news Orexin targeted drugs in clinical testing:
1 Like
Here’s the current landscape of orexin (OX2R) agonists in clinical development, ranked by anticipated availability — soonest first. Note these are the “wake-promoting” orexin-2 receptor agonists for narcolepsy/sleep disorders, which is where essentially the entire orexin-agonist field sits today.
Ranked by anticipated availability
| Drug (company) | Stage / Phase 3 status | Est. Phase 3 completion | Anticipated launch (if successful) |
|---|---|---|---|
| Oveporexton (TAK-861) — Takeda | Phase 3 complete (FirstLight/RadiantLight in NT1, all endpoints met). NDA accepted, FDA Priority Review, PDUFA Q3 2026 | Done (NT1); NT2 Phase 3 ongoing | H2 2026 / late 2026(US, NT1) — clear front-runner |
| Alixorexton (ALKS-2680) — Alkermes | Phase 3 Brilliance studies initiated Q1 2026 (NT1 & NT2); IH program planned | ~2028 | ~2029 |
| Cleminorexton (ORX750) — Centessa (being acquired by Eli Lilly, close expected Q3 2026) | Registrational/Phase 3 program initiated Q1 2026 (NT1, NT2, IH) | ~2028 | ~2029 |
| TAK-360 — Takeda | Phase 1 → early Phase 2; oral, for NT2 & IH; FDA Fast Track | ~2029–2030 | ~2030+ |
| ORX142 — Centessa/Lilly | Phase 1, clinical studies expanding Q1 2026 | ~2029–2030 | ~2030+ |
| ORX489 — Centessa/Lilly | Phase 1 (IND-stage) | later | early 2030s |
| TAK-495 — Takeda | Early/Phase 1 | later | early 2030s |
| BP1.15205 — Harmony Biosciences | Phase 1; PK data expected mid-2026 | later | early 2030s |
Stalled / discontinued (for completeness)
- JZP-441 (DSP-0187) — Jazz/Sumitomo: Phase 1 paused over visual disturbances and cardiovascular effects; not advancing.
- Danavorexton (TAK-925) — Takeda: IV agent, proof-of-concept established but discontinued for narcolepsy.
- TAK-994 — Takeda: oral, discontinued earlier due to hepatotoxicity (superseded by oveporexton).
Key takeaways
Oveporexton is in a class of its own — it’s the only one with completed Phase 3 data and a pending FDA decision, so it should be the first orexin agonist to market, realistically late 2026, initially for narcolepsy type 1.
Alixorexton and cleminorexton (ORX750) are the clear second wave, both having just entered Phase 3 in Q1 2026, putting them on roughly parallel ~2028 readout / ~2029 launch trajectories, with broader label ambitions (NT1, NT2, and idiopathic hypersomnia). Everything else is Phase 1/early stage, so any launch is 2030 or later and far less certain.
One caveat: only the oveporexton date is firm (tied to an actual PDUFA date). All later dates are my estimates built from standard timelines — roughly 2 years of Phase 3 plus ~10–12 months of regulatory review — and will shift with trial enrollment, readouts, and filing strategy.
Sources:
- Takeda — Positive Phase 3 oveporexton results
- Takeda — FDA accepts NDA / Priority Review, PDUFA Q3 2026
- Alkermes — Phase 3 Brilliance studies initiated
- Centessa Q3 2025 update — ORX750 registrational program
- BioSpace — Lilly’s $6.3B Centessa acquisition
- Harmony Biosciences 8-K — BP1.15205 Phase 1 PK mid-2026
- NeurologyLive — Advances in orexin therapies
- Sleep Review — Jazz halts JZP-441 (DSP-0187)
- PMC review — OX2R agonists for narcolepsy type 1
New data released, and looking good:
Takeda shared results from 2 pivotal studies at the SLEEP 2026 Annual Meeting which showed that oveporexton (TAK-861) improved daily functioning, cognition, and sleep-related symptoms associated with narcolepsy type 1 (NT1).1 Psychiatric Times interviewed Elena Koundourakis, PhD, the head of the Orexin Franchise Development & Neuroscience Programs at Takeda, to learn more.
These new data, she said, suggest restoring orexin signaling may improve “the full spectrum” of NT1 symptoms — not just excessive daytime sleepiness and cataplexy but also cognition, functioning, and nighttime sleep.
https://www.psychiatrictimes.com/view/reducing-microsleeps-oveporextons-impact-on-patient-outcomes
2 Likes
Spotlight On: Alkermes’ NT2 data boost case for broad potential of orexins
PUBLISHED : JUNE 19, 2026
Much of the excitement around orexin 2 receptor (OX2R) agonists hinges on their ability to impact diseases not driven directly by an orexin deficiency, meaning this week’s update for Alkermes’ alixorexton is a win for it and perhaps the entire class.
The backstory
A consensus has already crystallised around an expectation that OX2R agents are poised to revolutionise narcolepsy type 1 (NT1), a condition driven by an insufficiency in the neuropeptide orexin.
Several therapies have generated encouraging clinical data supporting this hypothesis. These include Takeda’s oveporexton and alixorexton, along with cleminorexton from Centessa Pharmaceuticals, which is in the process of being bought out by Eli Lilly for $6.3 billion.
Important as the success of the class is in NT1, some of the more eye-popping sales projections for alixorexton and other OX2R agonists are based instead on their ability to succeed in adjacent indications, beginning — but not ending — with narcolepsy type 2 (NT2).
What happened
On Wednesday, Alkermes presented detailed results from the Vibrance-2 sleep study in which once-daily alixorexton was confirmed as hitting the primary endpoints, demonstrating a significant benefit on the maintenance of wakefulness test (MWT) and Epworth Sleepiness Scale (ESS), in 93 patients with NT2 after eight weeks.
Interestingly, and more tantalisingly, the company also unveiled data looking at exploratory measures beyond wakefulness, which suggest that alixorexton achieved a meaningful improvement on patient-reported outcomes focused on cognition and fatigue. The benefits were observed as early as week two and continued throughout the 13-week open-label extension study.
Why this matters
“When Alkermes showed randomised data in NT1 on cognition, etcetera, it was very encouraging, but it wasn’t 100% clear if we could generalise that to larger indications, because NT1 pts have very low baseline orexin levels,” noted Evercore ISI analyst Umer Raffat.
These new functional findings are especially impressive, according to Raffat, because NT2 is a condition where patients have more normal orexin levels, so the fact that they responded to a therapy like alixorexton suggests that agonising OX2R is having a more profound physiological impact.
3 Likes
Full press release on this announcement:
https://investor.alkermes.com/news-releases/news-release-details/alkermes-alixorexton-demonstrated-sustained-improvement